Leigh Syndrome Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Leigh Syndrome Market Trends and Insights

Increasing Genetic Testing and Earlier Diagnosis

Earlier genetic testing is a central near-term factor for the Leigh syndrome market because it changes the point at which patients can enter specialist care. The NCBI Genetic Test Registry listed 271 sequencing-based tests for Leigh syndrome spectrum from 32 laboratories worldwide in July 2025. The Global Patient Registry reported that it included more than 400 participants across 48 countries, showing the breadth of the patient identification effort. Earlier confirmation allows sponsors to identify people with defined mutations before trial enrollment begins. Thiogenesis structured its Phase 2a enrollment around confirmed genetic subtypes, which shows the practical value of these patient pools. The NAMDC, which is supported through the NIH Rare Diseases Clinical Research Network, provides a national structure that links diagnosis, specialist care, and research participation. More confirmed cases can also make the clinical needs of the Leigh syndrome market clearer to treatment centers and program sponsors.

Progress in Mitochondrial Targeted and Gene Therapies

Mitochondrial-targeted and gene therapies are changing the development outlook for the Leigh syndrome market. A 2026 Nature Biotechnology study corrected disease-associated mitochondrial variants in rat zygotes with engineered base editors and reported a 53.00% average restoration of wild-type alleles ^{[1]Chen, L. et al. "A mitochondrial disease model is generated and corrected using engineered base editors in rat zygotes." Nature Biotechnology 44, 382–386, 2026. https://doi.org/10.1038/s41587-025-02684-y}. A 2025 Brain study found that focused-ultrasound-assisted AAV9 delivery crossed the blood-brain barrier and improved survival, cardiac function, and brain function in Ndufs4 knockout mice. These findings address a major delivery barrier for therapies intended to reach the central nervous system. Taysha’s TSHA-104 program illustrates the mutation-specific approach for SURF1-associated Leigh syndrome and has received Rare Pediatric Disease and Orphan Drug designations. A refined AAV9 vector design reported in 2025 maintained efficacy in rat models while reducing cytotoxicity, which may strengthen safety planning before a future resubmission.

Growth of Patient Registries and Trial Ready Cohorts

Patient registries connect genetic diagnosis with trial planning in the Leigh syndrome market. The MSeqDR PMD Virtual Registry surpassed 9,000 de-identified primary mitochondrial disease cases in November 2024, including 2,000 Leigh syndrome cases identified through literature mining and expert curation. The Leigh Syndrome International Consortium is actively tracking at least 150 genetically confirmed patients through its natural history study. These records give sponsors a clearer view of patient history, genotype, and potential eligibility before a study opens. The Cure Mito Foundation mapped registry data fields to CDASH clinical data standards in 2024, improving compatibility with regulatory submission requirements. Standardized registry datasets may also support external control groups for single-arm rare disease studies, reducing the number of participants needed for a pivotal study.

Expansion of Rare Mitochondrial Disease Research Funding

Research funding supports the discovery and clinical infrastructure needed for the Leigh syndrome market. The University of Arkansas received USD 3.10 million from the NIH in 2024 for a 5-year study of pediatric mitochondrial disorder syndromes across neuronal, cardiac, and renal tissue models. Khondrion secured up to EUR 5.00 million (USD 5.48 million) in Dutch government Innovation Credit funding in 2025 to support the KHENERFIN Phase 3 program. The funding mix combines public support at earlier stages with private capital after proof-of-concept evidence has emerged. The NIH Rare Diseases Clinical Research Network had USD 26.00 million in fiscal year 2025 grants, including support for the NAMDC. Sustained research capacity can give smaller developers access to clinical sites and patient networks that would otherwise be difficult to build independently.

Genetic and Phenotypic Heterogeneity

Genetic and phenotypic heterogeneity limit the scale available to any single program in the Leigh syndrome market. Leigh syndrome can arise from more than 100 genes across mitochondrial and nuclear genomes. The same MT-ATP6 m.9176T>C variant can produce severe Leigh syndrome or the milder NARP phenotype, depending on heteroplasmy load. A program focused on SURF1-related disease may reach only 10.00% to 15.00% of patients, while MT-ATP6 programs serve a separate group. The SIMPATHIC trial is restricted to MT-ATP6-related disease and shows how genetic selection narrows each study population. This division complicates trial recruitment and reduces the revenue pool attached to a mutation-specific approval.

High Cost of Rare Disease Drug Development

Rare-disease development costs place a material constraint on the Leigh syndrome market. A Phase 2 study can enroll only 15 to 28 people but still requires good manufacturing practice production, safety monitoring, and regulatory reporting. The Sirolimus pilot enrolled 15 pediatric patients, while the OMEICOS PMD-OPTION study enrolled 28 patients with primary mitochondrial disease. OMEICOS reported positive Phase 2 results for OMT-28 in January 2026 and is preparing a pivotal study across European and U.S. sites. It also reported a positive FDA End-of-Phase 2 meeting and the need to move OMT-28 toward Phase 3. These conditions favor developers with specialist rare-disease capabilities, government support, or partners able to fund pivotal development.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Genetic Etiology: Nuclear Variants Anchor Market Volume, CoQ10 Subtype Leads Growth

Nuclear DNA-Associated Leigh Syndrome accounted for 58.24% of the Leigh syndrome market size by genetic etiology in 2025. Nuclear variants, including SURF1, NDUFAF6, and PDHA1, are prevalent in confirmed cases and have clearer molecular targets. The Global Patient Registry found that 64.00% of enrolled participants had nuclear DNA mutations. SURF1 represented 72.00% of the nuclear DNA mutation cohort in that registry. Mitochondrial DNA-Associated Leigh Syndrome is the second-largest category and is associated largely with MT-ATP6 and MT-ND subunit variants.

Coenzyme Q10 Deficiency is forecast to grow at an 11.42% CAGR through 2031. Improved sequencing can identify biosynthesis pathway mutations with greater precision. CoQ10 supplementation and next-generation analogs provide a clinically tractable route for this subtype. A registered drug-repurposing study is using iPSC-derived neuronal models to screen FDA- and EMA-approved compounds across nuclear and mitochondrial DNA-associated subtypes. PDH Deficiency remains a defined but underserved group that requires metabolic management, ketogenic diets, and thiamine supplementation.

By Treatment Type: Supportive Regimens Anchor Spending, Gene and RNA Therapies Reshape the Forecast

Supportive & Symptomatic Therapy accounted for 46.37% of the Leigh syndrome market in 2025. This category reflects the continuing use of intensive care, mechanical ventilation, seizure management, and nutritional support. These services remain essential because approved disease-modifying therapies are not available. Vitamin and cofactor supplementation and antioxidant therapy form the second-largest current spending block. Riboflavin, CoQ10, thiamine, and alpha-lipoic acid have long been used in clinical management.

Gene & RNA-Based Therapies are forecast to grow at a 24.86% CAGR through 2031. AAV9 delivery programs, mitochondrial base editing, and mitoTALEN correction tools support this forecast. Improved vector design is intended to preserve efficacy while lowering cytotoxicity in preclinical models. Mitochondrial Replacement & Advanced Therapies remain early in commercial development. Their clinical progress will depend on adequate safety evidence and on the ability to administer treatment within specialist pediatric services.

By Route of Administration: Oral Dominance Persists, CNS Directed Routes Scale at Highest Velocity

Oral administration held 67.85% in 2025. Cofactor supplementation and chronic small-molecule therapies support the leading position of oral products. Thiogenesis developed TTI-0102 as an oral prodrug for sustained cysteamine exposure. OMEICOS uses a 24.00 mg once-daily oral dose for OMT-28. Enteral sirolimus administered twice daily through a gastrostomy tube reflects the practical needs of hospitalized pediatric patients. This route also fits the continuing need for regular care outside inpatient crisis management.^{[2]OMEICOS Therapeutics, “OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases,” OMEICOS Therapeutics, omeicos.com}

Intracerebroventricular administration is forecast to grow at a 22.15% CAGR through 2031. This route is linked to the gene therapy pipeline and the need to deliver treatment to the central nervous system. TSHA-104 uses intrathecal delivery, while focused ultrasound could provide a noninvasive method to assist AAV9 delivery across the blood-brain barrier. Hospital-administered, single-dose procedures will require surgical capabilities and intensive monitoring. Intravenous administration continues to support acute metabolic crisis management in tertiary hospitals, while subcutaneous administration may grow if antibody and enzyme replacement candidates progress.

By Care Setting: Tertiary Hospitals Hold the Spending Majority, Disease Centers Scale Fastest

Tertiary Hospitals accounted for 42.91% of the Leigh syndrome market in 2025. Recurrent metabolic crises can require intensive care, mechanical ventilation, and coordination among multiple specialists. Pediatric Neurology Centers are the second-largest setting because patients require MRI monitoring and neurodevelopmental assessment. Specialty Clinics and Rehabilitation Centers support patients after acute episodes. They provide physiotherapy, nutrition management, and palliative care for ongoing needs.

Mitochondrial Disease Centers of Excellence are forecast to expand at an 18.74% CAGR through 2031. These centers bring metabolic specialists, genetic counselors, neuroimaging, and active trial programs into a single care setting. NAMDC member centers serve as both referral sites and trial sites, concentrating genetically characterized patients. The KHENERFIN Phase 3 study uses specialist centers across European countries for enrollment. Home Healthcare remains a smaller setting that may serve families of longer-surviving patients, including adult-onset presentations reported in Chinese cohorts.

Geography Analysis

North America held 41.28% of the Leigh syndrome market in 2025. The region benefits from rare-disease pathways, specialist centers, and structured research networks. The NAMDC supports connections between diagnosed patients, clinical research sites, and specialist services through the NIH Rare Diseases Clinical Research Network. Canada supports development activity through Thiogenesis, while Mexico has earlier-stage specialist neurological care access. These features give the North American Leigh syndrome market a more established clinical infrastructure than many other regions.

Europe is the second-largest regional presence in the Leigh syndrome market. Khondrion dosed the first patient in the pivotal KHENERFIN Phase 3 study in April 2026. The EMA granted orphan designation to sonlicromanol for inherited mitochondrial oxidative phosphorylation defects in July 2025. The United Kingdom, France, Italy, and Spain add coordinated referral capability through specialist mitochondrial and rare metabolic centers.

Asia-Pacific is forecast to grow at a 15.38% CAGR through 2031. Japan completed a Phase 3 trial of SPP-004, which showed stabilization or improvement in central nervous system symptoms in 50.00% of enrolled patients.^{[3]PLOS ONE, "A phase III double-blind, placebo-controlled, randomized withdrawal trial of 5-aminolevulinic acid hydrochloride with sodium ferrous citrate for efficacy and safety in patients diagnosed as Leigh syndrome." 2025. https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0332283} China offers a substantial diagnostic opportunity, as Leigh syndrome represented 28.00% of genetically confirmed pediatric mitochondrial cases in a 2025 multicenter cohort. The same study reported a median onset of 1.15 years for nuclear DNA subtypes and 5.42 years for mitochondrial DNA subtypes. India, South Korea, and Australia are building rare-disease research capacity and genomics laboratory networks.